This is a real-world medical entrance exam question, please give the true answer based on the question and selection. Topic name: Chemotherapy, Subject name: Pharmacology
Tildrakizumab was approved in March 2018 for 
Select and explain. 
A. Psoriasis, B. HIV, C. Rheumatoid ahritis, D. Hepatitis C
A: Psoriasis
Answer: A: Psoriasis 
Explanation: Tildrakizumab was designed to block interleukin-23, a cytokine that plays an impoant role in managing the immune system and autoimmune disease. It is approved for the treatment of moderate-to-severe plaque psoriasis.Ref: